Skip to main content

Advertisement

SpringerLink
Log in

Clinicopathologic significance of β-catenin and matrix metalloproteinase-2 expression in non-small cell lung cancer

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

The purpose of this study was to analyze β-catenin and matrix metalloproteinase-2 (MMP-2) expression in non-small cell lung cancer (NSCLC) and to investigate the association between their expression and clinicopathologic characteristics of NSCLC patients. Immunohistochemistry was performed to examine β-catenin and MMP-2 protein expression in 39 resected NSCLC samples and 8 adjacent normal lung tissues. Statistical analysis with SPSS13.0 software was performed to investigate the association between β-catenin and MMP-2 expression and clinicopathologic features of the patients. Expression of cytosolic β-catenin in NSCLC tissue was significantly higher than that in normal tissues (P < 0.001). In addition, cytosolic protein expression of β-catenin in lung squamous cell carcinoma was significantly elevated compared to that in lung adenocarcinoma (P = 0.02). However, cell membrane protein expression of β-catenin in squamous cell carcinoma was lower than that in adenocarcinoma (P = 0.041). Cytosolic MMP-2 protein expression in NSCLC samples was significantly higher than that in normal tissues (P = 0.002). MMP-2 expression in N 1–2 NSCLC patients was significantly increased relative to N 0 patients (P = 0.019). However, statistical analysis showed no correlation between β-catenin and MMP-2 expression in NSCLC samples. Collectively, our results show that cytosolic protein expression of β-catenin in NSCLC samples is increased relative to normal lung tissues. Also, expression of β-catenin is significantly elevated in squamous cell carcinoma compared to that in lung adenocarcinoma subtypes. Additionally, MMP-2 expression in N 1–2 NSCLC tissues is higher than that in N 0 lung tissue. There is no correlation between β-catenin and MMP-2 expression in NSCLC, and our study suggests that evaluation of β-catenin and MMP-2 expression may have potential in diagnosis and progression in patients with NSCLC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5):584–94.

    PubMed  Google Scholar 

  2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29.

    Article  PubMed  Google Scholar 

  3. Kashima T, Kawaguchi J, Takeshita S, Kuroda M, Takanashi M, Horiuchi H, et al. Anomalous cadherin expression in osteosarcoma. Possible relationships to metastasis and morphogenesis. Am J Pathol. 1999;155(5):1549–55.

    Article  PubMed  CAS  Google Scholar 

  4. Pagaki E, Patsouris E, Gonidi M, Athanassiadou AM, Maurikakis M, Athanassiades P, et al. The value of E-cadherin/beta-catenin expression in imprints of NCSLC: relationship with clinicopathological factors. Diagn Cytopathol. 2010;38(6):419–24.

    PubMed  Google Scholar 

  5. Lu Z, Lu N, Li C, Li F, Zhao K, Lin B, et al. Oroxylin A inhibits matrix metalloproteinase-2/9 expression and activation by up-regulating tissue inhibitor of metalloproteinase-2 and suppressing the ERK1/2 signaling pathway. Toxicol Lett. 2012;209(3):211–20.

    Article  PubMed  CAS  Google Scholar 

  6. Sims JD, McCready J, Jay DG. Extracellular heat shock protein (Hsp)70 and Hsp90alpha assist in matrix metalloproteinase-2 activation and breast cancer cell migration and invasion. PLoS ONE. 2011;6(4):e18848.

    Article  PubMed  CAS  Google Scholar 

  7. Alberg AJ, Brock MV, Samet JM. Epidemiology of lung cancer: looking to the future. J Clin Oncol. 2005;23(14):3175–85.

    Article  PubMed  Google Scholar 

  8. Takahashi M, Tsunoda T, Seiki M, Nakamura Y, Furukawa Y. Identification of membrane-type matrix metalloproteinase-1 as a target of the beta-catenin/Tcf4 complex in human colorectal cancers. Oncogene. 2002;21(38):5861–7.

    Article  PubMed  CAS  Google Scholar 

  9. He B, Barg RN, You L, Xu Z, Reguart N, Mikami I, et al. Wnt signaling in stem cells and non-small-cell lung cancer. Clin Lung Cancer. 2005;7(1):54–60.

    Article  PubMed  CAS  Google Scholar 

  10. Lai SL, Chien AJ, Moon RT. Wnt/Fz signaling and the cytoskeleton: potential roles in tumorigenesis. Cell Res. 2009;19(5):532–45.

    Article  PubMed  CAS  Google Scholar 

  11. Mukherjee N, Bhattacharya N, Alam N, Roy A, Roychoudhury S, Panda CK. Subtype-specific alterations of the Wnt signaling pathway in breast cancer: clinical and prognostic significance. Cancer Sci. 2012;103(2):210–20.

    Article  PubMed  CAS  Google Scholar 

  12. Retera JM, Leers MP, Sulzer MA, Theunissen PH. The expression of beta-catenin in non-small-cell lung cancer: a clinicopathological study. J Clin Pathol. 1998;51(12):891–4.

    Article  PubMed  CAS  Google Scholar 

  13. Zang D, Li X, Zhang L. 14–3-3zeta Overexpression and abnormal beta-catenin expression are associated with poor differentiation and progression in stage I non-small cell lung cancer. Clin Exp Med. 2010;10(4):221–8.

    Article  PubMed  CAS  Google Scholar 

  14. Kim YT, Choi EK, Kim JW, Kim DK, Kim SH, Yang WI. Expression of E-cadherin and alpha-, beta-, gamma-catenin proteins in endometrial carcinoma. Yonsei Med J. 2002;43(6):701–11.

    PubMed  CAS  Google Scholar 

  15. Chelidonis G, Kavantzas N, Patsouris E, Pagaki E, Athanasiadou AM, Agrogiannis G, et al. DNA ploidy, E-cadherin, beta-catenin expression and their clinicopathologic significance in imprints of non-small cell lung cancer. Anal Quant Cytol Histol. 2009;31(5):332–9.

    PubMed  Google Scholar 

  16. Maeda D, Shibahara J, Sakuma T, Isobe M, Teshima S, Mori M, et al. beta-catenin (CTNNB1) S33C mutation in ovarian microcystic stromal tumors. Am J Surg Pathol. 2011;35(10):1429–40.

    Article  PubMed  Google Scholar 

  17. Xu HT, Wang L, Lin D, Liu Y, Liu N, Yuan XM, et al. Abnormal beta-catenin and reduced axin expression are associated with poor differentiation and progression in non-small cell lung cancer. Am J Clin Pathol. 2006;125(4):534–41.

    PubMed  CAS  Google Scholar 

  18. Chiu CG, Chan SK, Fang ZA, Masoudi H, Wood-Baker R, Jones SJ et al. Beta-catenin expression is prognostic of improved non-small cell lung cancer survival. Am J Surg. 2012;203(5):654–9.

    Google Scholar 

  19. Stetler-Stevenson WG. Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix. Am J Pathol. 1996;148(5):1345–50.

    PubMed  CAS  Google Scholar 

  20. Hida Y, Hamada JI. Differential expressions of matrix metalloproteinases, a disintegrin and metalloproteinases, and a disintegrin and metalloproteinases with thrombospondin motifs and their endogenous inhibitors among histologic subtypes of lung cancers. Anticancer Agents Med Chem. 2012;12(7):744–52.

    Google Scholar 

  21. Shao W, Wang W, Xiong XG, Cao C, Yan TD, Chen G, et al. Prognostic impact of MMP-2 and MMP-9 expression in pathologic stage IA non-small cell lung cancer. J Surg Oncol. 2011;104(7):841–6.

    Article  PubMed  CAS  Google Scholar 

  22. Xu X, Sun PL, Li JZ, Jheon S, Lee CT, Chung JH. Aberrant Wnt1/beta-catenin expression is an independent poor prognostic marker of non-small cell lung cancer after surgery. J Thorac Oncol. 2011;6(4):716–24.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

We would like to thank the staff and research personnel in the Department of Thoracic Surgery at the First Bethune Hospital of Jilin University and the Department of Pathology of Jilin University. This work was supported by the project of Technology Development of Jilin Province (200705171).

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Thoracic Surgery, First Bethune Hospital of Jilin University, Changchun, Jilin, People’s Republic of China

    Guang-Hu Li, Yong-Sheng Cui, Qi-Yu Wu & Xiong-Ji Zhang

  2. China-Japan Union Hospital of Jilin University, 126 Xiantai St, Changchun, Jilin, 130033, China

    Yu-Fei Gao

Authors
  1. Guang-Hu Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yong-Sheng Cui
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Qi-Yu Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiong-Ji Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yu-Fei Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Xiong-Ji Zhang or Yu-Fei Gao.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Li, GH., Cui, YS., Wu, QY. et al. Clinicopathologic significance of β-catenin and matrix metalloproteinase-2 expression in non-small cell lung cancer. Med Oncol 30, 437 (2013). https://doi.org/10.1007/s12032-012-0437-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-012-0437-z

Keywords

Search

Navigation